Abstract
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
http://creativecommons.org/licenses/by-nc/4.0/
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Executive summary of recommendations
Prevention of hepatocellular carcinoma
-
National policies should be implemented to prevent transmission of viral hepatitis, reduce alcohol abuse and encourage lifestyle changes to minimise risks of obesity and metabolic syndrome (evidence high; recommendation strong).
-
Vaccination against hepatitis B virus (HBV) should be carried out in all infants (as part of the childhood immunisation programme), people at high risk of exposure to the virus or complications of the disease (including those who inject drugs) and individuals already exposed to the virus (including infants born to HBV-positive mothers, people with needle stick injury) (evidence high; recommendation strong).
-
Chronic liver diseases should be treated with the aim of preventing inflammation and progression of fibrosis (evidence high; recommendation strong).
-
Patients with chronic infection should be treated with antiviral therapy to maintain suppression of viral replication (evidence high; recommendation strong).
-
Patients with chronic hepatitis C infection should be treated with the aim of achieving viral eradication (evidence high, recommendation strong).
-
In cirrhotic patients with chronic viral hepatitis, effective antiviral treatment reduces (but does not eliminate) the risk of hepatocellular carcinoma (HCC) and is recommended (evidence moderate; recommendation strong).
-
Effective antiviral therapy should be maintained or instituted in patients with hepatitis C and hepatitis B who undergo surgical or ablative treatments for HCC (evidence high; recommendation strong).
-
Adjuvant therapy with atezolizumab and bevacizumab might improve recurrence-free survival after surgery or ablation, but longer-term follow-up is required before it can be recommended (evidence moderate; recommendation moderate).
Surveillance for hepatocellular carcinoma
-
HCC surveillance with 6-monthly US scan and α-fetoprotein (AFP) measurement should be considered in people with cirrhosis, and certain subgroups of patients with chronic HBV infection (evidence strong, recommendation strong).
-
The absolute risk of HCC and the potential harms of surveillance should be discussed individually before a person is enrolled in surveillance (evidence moderate; recommendation strong).
-
Surveillance is not recommended in patients who are not fit for cancer-specific therapy. Examples include those with decompensated cirrhosis (Child B8 or worse) who would not be candidates for liver transplant if HCC was diagnosed, and those with very impaired performance status (Eastern Cooperative Oncology Group (ECOG) category 2 or worse) (evidence moderate; recommendation strong).


